A Survey of the Structures of US FDA Approved Combination Drugs

被引:209
|
作者
Das, Pradipta [1 ]
Delost, Michael D. [1 ]
Qureshi, Munaum H. [1 ]
Smith, David T. [1 ]
Njardarson, Jon T. [1 ]
机构
[1] Univ Arizona, Dept Chem & Biochem, 1306 East Univ Blvd, Tucson, AZ 85721 USA
基金
美国国家科学基金会;
关键词
PHARMACOKINETIC PROPERTIES; BACTERICIDAL AGENT; ANTIVIRAL ACTIVITY; CANCER-THERAPY; MANAGEMENT; HISTORY; HYDROCHLOROTHIAZIDE; MECHANISMS; INHIBITOR; DISCOVERY;
D O I
10.1021/acs.jmedchem.8b01610
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed.
引用
收藏
页码:4265 / 4311
页数:47
相关论文
共 50 条
  • [1] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [2] US-FDA Approved Drugs in 2020 and 2021: A Review
    Passi, Indu
    Salwan, Sushant
    Kumar, Bhupinder
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (12) : 1273 - 1297
  • [4] Highlights on Fluorine-Containing Drugs Approved by US FDA in 2023
    Ali, Saghir
    Bolinger, Andrew A.
    Zhou, Jia
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2024, 24 (10) : 843 - 849
  • [5] Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
    Kevin A. Scott
    Jon T. Njardarson
    Topics in Current Chemistry, 2018, 376
  • [6] Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
    Scott, Kevin A.
    Njardarson, Jon T.
    TOPICS IN CURRENT CHEMISTRY, 2018, 376 (01)
  • [8] Aubagio approved by US FDA
    O'Hare, Alice
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (08) : 703 - 703
  • [9] Votrient™ approved by the US FDA
    O'Hare, Alice
    FUTURE ONCOLOGY, 2012, 8 (06) : 648 - 648
  • [10] Teriflunomide approved by the US FDA
    O'Hare, Alice
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (06) : 615 - 615